Literature DB >> 19473660

The CD163-expressing macrophages recognize and internalize TWEAK: potential consequences in atherosclerosis.

Juan A Moreno1, Begoña Muñoz-García, Jose L Martín-Ventura, Julio Madrigal-Matute, Josune Orbe, Jose A Páramo, Luis Ortega, Jesús Egido, Luis M Blanco-Colio.   

Abstract

BACKGROUND: CD163 is a new potential scavenger receptor of Tumor necrosis factor-like weak inducer of apoptosis (TWEAK) which elicits diverse biologic actions involved in atherosclerosis. We have analyzed the importance of TWEAK-CD163 interaction in atherosclerosis.
METHODS: TWEAK and CD163 interaction was studied in cultured human macrophages. Moreover, TWEAK and CD163 expression was analyzed in carotid atherosclerotic plaques (immunohistochemistry) and plasma (ELISA). We have also assessed their potential association with intima/media thickness (IMT) in asymptomatic subjects.
RESULTS: In vitro studies revealed that CD163-expressing macrophages can bind and internalize TWEAK protein exogenously added from supernatants. Accordingly, we observed an inverse correlation between the expression of CD163 and TWEAK (r=-0.51; p=0.008) in the shoulder region of atherosclerotic plaques obtained from 25 patients undergoing carotid endarterectomy. The same trend was observed when we analyzed the plasma concentration of both proteins in 90 subjects free from clinical cardiovascular disease (r=-0.25; p=0.016) in which carotid ultrasonography was performed to determine IMT. In these subjects, we found a positive correlation between sCD163 and IMT (r=0.36; p<0.001) and between sCD163-sTWEAK ratio and IMT (r=0.51; p<0.001). This association remained significant after adjusting for traditional cardiovascular risk factors and inflammatory markers explaining 39% (sCD163) or 48% (sCD163-sTWEAK ratio) of IMT variance.
CONCLUSIONS: Our results suggest that TWEAK-CD163 interaction takes place in vivo, probably decreasing TWEAK plasma concentration. Furthermore, we have observed that CD163-TWEAK plasma ratio is a potential biomarker of clinical and subclinical atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19473660     DOI: 10.1016/j.atherosclerosis.2009.04.033

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  69 in total

1.  Evaluation of serum sTWEAK and sCD163 levels in patients with acute and chronic coronary artery disease.

Authors:  Abdulselam Ilter; Cihan Orem; Fulya Balaban Yucesan; Mursel Sahin; Yusuf Hosoglu; Elif Kurumahmutoglu; Serap Ozer Yaman; Asim Orem
Journal:  Int J Clin Exp Med       Date:  2015-06-15

Review 2.  TWEAK as a target for therapy in systemic lupus erythematosus.

Authors:  Rui-Xue Leng; Hai-Feng Pan; Wei-Zi Qin; Chao Wang; Li-Li Chen; Jin-Hui Tao; Dong-Qing Ye
Journal:  Mol Biol Rep       Date:  2010-04-01       Impact factor: 2.316

3.  Combined therapy with renin-angiotensin system and calcium channel blockers in type 2 diabetic hypertensive patients with proteinuria: effects on soluble TWEAK, PTX3, and flow-mediated dilation.

Authors:  Mahmut Ilker Yilmaz; Juan Jesús Carrero; Jose Luis Martín-Ventura; Alper Sonmez; Mutlu Saglam; Turgay Celik; Halil Yaman; Mujdat Yenicesu; Tayfun Eyileten; Juan Antonio Moreno; Jesús Egido; Luis Miguel Blanco-Colio
Journal:  Clin J Am Soc Nephrol       Date:  2010-04-29       Impact factor: 8.237

4.  Identification of CD163 as an antiinflammatory receptor for HMGB1-haptoglobin complexes.

Authors:  Huan Yang; Haichao Wang; Yaakov A Levine; Manoj K Gunasekaran; Yongjun Wang; Meghan Addorisio; Shu Zhu; Wei Li; Jianhua Li; Dominique Pv de Kleijn; Peder S Olofsson; H Shaw Warren; Mingzhu He; Yousef Al-Abed; Jesse Roth; Daniel J Antoine; Sangeeta S Chavan; Ulf Andersson; Kevin J Tracey
Journal:  JCI Insight       Date:  2016-05-19

5.  The association of high sCD163/sTWEAK ratio with cardiovascular disease in hemodialysis patients.

Authors:  Crina Claudia Rusu; Simona Racasan; Ina Maria Kacso; Liviu Ghervan; Diana Moldovan; Alina Potra; Ioan Mihai Patiu; Cosmina Bondor; Mirela Gherman Caprioara
Journal:  Int Urol Nephrol       Date:  2015-10-03       Impact factor: 2.370

6.  The CD163 long-range scavenger receptor cysteine-rich repeat: expression, purification and X-ray crystallographic characterization.

Authors:  Rui Li; Hongfang Ma; Longguang Jiang; Songlin Qiao; Yubao Zhi; Mingdong Huang; Ruiguang Deng; Gaiping Zhang
Journal:  Acta Crystallogr F Struct Biol Commun       Date:  2018-04-25       Impact factor: 1.056

7.  Soluble TWEAK levels are independently associated with coronary artery disease severity in patients with stage 2-3 kidney disease.

Authors:  Alper Azak; Mehmet Fatih Akdoğan; Nazım Denizli; Bülent Huddam; Gülay Koçak; Murat Gücün; Mustafa Adem Tatlısu; Recep Demirci; Bilal Yılmaz; Mehmet Dikeç; Murat Bakırtaş; Ibrahim Akdağ; Murat Duranay
Journal:  Int Urol Nephrol       Date:  2013-09-17       Impact factor: 2.370

8.  Expression of CD163 prevents apoptosis through the production of granulocyte colony-stimulating factor in meningioma.

Authors:  Hiromi Kanno; Hiroshi Nishihara; Lei Wang; Sayaka Yuzawa; Hiroyuki Kobayashi; Masumi Tsuda; Taichi Kimura; Mishie Tanino; Shunsuke Terasaka; Shinya Tanaka
Journal:  Neuro Oncol       Date:  2013-03-28       Impact factor: 12.300

9.  The metabolic hormone FGF21 is associated with endothelial dysfunction in hemodialysis patients.

Authors:  Crina Claudia Rusu; Simona Racasan; Ina Maria Kacso; Diana Moldovan; Alina Potra; Dacian Tirinescu; Cristian Budurea; Remus Orasan; Ioan Mihai Patiu; Cosmina Ioana Bondor; Dan Vladutiu; Mirela Gherman Caprioara
Journal:  Int Urol Nephrol       Date:  2016-12-10       Impact factor: 2.370

Review 10.  CD163 and inflammation: biological, diagnostic, and therapeutic aspects.

Authors:  Anders Etzerodt; Søren K Moestrup
Journal:  Antioxid Redox Signal       Date:  2012-10-19       Impact factor: 8.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.